|
2023–2025 |
A randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 In patients With Idiopathic Pulmonary Fibrosis (IPF) |
|
2023–2025 |
ClinicAl study for the effectiveness of Roflumilast treatment in COPD Greek patients based On standard clinical practice |
|
2023–2025 |
A randomized, double-blind, four-arm, active- and placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, safety and dose-response of LYT-100 in patients with idiopathic pulmonary fibrosis (IPF) |
|
2023–2025 |
A Randomized, open-label phase study 2-3 study to comparative cobolimab + dostarlimab + docetaxel against dostarlimab + docetaxel against doctaxel doctaxel doctaxel in participation l)1 therapy and chemotherapy (COSTAR LUNG) |
|
2022–2023 |
Clinical practice data (real world data) relatively to escalation or de-escalation of inhaled therapies in patients with COPD. A multicenter, non-invasive clinical observational study in COPD patients in Greece for the determination of the reasons for the escalation or de-escalation of inhaled COPD treatments (STEPINCOPD) |
|
2022–2027 |
Exploiting the results of clinical research in the field of pylmonology - lung immunology |
|
2021–2025 |
Conference organisation on current pneumonological topics |
|
2021–2024 |
A Phase 3, Randomized, Double-Blind ,Plaxebo-Controlled Study to Access the Efficacy,Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis-Th ASPEN Study |
|
2021–2023 |
A phase iii, randomized, double blind, placebo controlled trial for the evaluation of the effevtiveness and safety of prm-151 in patients with idiopathic pulmonary fibrosis |
|
2021–2025 |
A phase iii, open labeling study-extension to evaluate the long-term safety and effectiveness of prm-151 in patients with idiopathic pulmonary fibrosis |
|
2019–2025 |
Investigation and monitoring of patients with asthma |
|
2019–2020 |
Incidence and prevalence of interstitial lung disease and their progressive fibrosing phenotypes in 6 European countries |
|
2019–2021 |
A phase, randomized, double blind, parallel –group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses og GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis |
|
2019–2023 |
Investigating trends in quality of life in patients with idiopathic pulmonary fibrosis (IPF) treated with nintentanib |
|
2018–2018 |
Convention: "Immunological promenades" |
|
2018–2020 |
A 52 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY AND SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA |
|
2018–2019 |
Correlation of the survival of patiens with idiopathic pulmonary fibrosis with biological agents |
|
2018–2020 |
A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study to compare the efficacy and safety of QVM149 with a free triple combination of salmeterol/ fluticasone+ tiotropium in patients with uncontrolled asthma |
|
2017–2018 |
|
|
2017–2025 |
Staging and follow up of IFP patients |
|
2017–2020 |
Α multicenter, post-marketing, non-interνentional, obserνational study to eνaluate quality of life in patients in greece with
idiopathic pulmonary fibrosis under treatment with Pirfenidone - The Pneumon Study |
|
2017–2022 |
Investigating idiopathic pulmonary fibrosis in Greece (INDULGE - IPF) |
|
2016–2026 |
Presentations medical issues with objects: obstructive lung diseases-asthma and interstitial lung-pulmonary fibrosis. |
|
2016–2023 |
Registry of charavteristics and follow-up of Greek patients with idiopathic pulmonary fibrosis |
|
2016–2016 |
Idiopathic pulmonary fibrosis: from diagnosis to the treatment |
|
2015–2016 |
Current trends in pharmacotherapy of obstructrive airway diseases |
|
2015–2016 |
New trends in asthma management |
|
2015–2015 |
Th erole of the extra fine fixed powder inhaler combination in the treatment of asthma |
|
2015–2015 |
Biological agents in asthma. The role of anti-IgE and anti-IL-5 in the treatment of severe asthma |
|
2015–2015 |
Update in lung diseases |
|
2014–2014 |
Uncontrolled allergic asthma:Mechanisms and therapeutic targets |
|
2014–2015 |
Current therapeutic approach of idiopathic pulmonary fibrosis. |
|
2014–2014 |
The therapeutic role of steroids in lung disease. |
|
2014–2014 |
Control of asthma : A permanent challenge |
|
2011–2013 |
A randomized,placebo-controlled,dose -ranging, multicentre trial of QAWA039(1-450mg p.o)to investigate the effect of FEV1 and ACQ in patients with moderate -to-severe, persistent, allergic asthma,inadequately controlled with ICS therapy |
|
2010–2012 |
A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50μg o.d.) vs NVA237 (50μg o.d) and open-label tiotropium (18μg o.d) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary diseas (COPD) |
|
2008–2008 |
Comparison of tiotropium to salmeterol in asthmatic patients homozygous for B16-Arg-Arg |
|
2007–2012 |
Evaluation of bronchial asthma severity and complation with bronchial hyperactivity and inflamation in different asthma phenotypes |
